On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Five9, Inc. FIVN, saying the stock is “way too cheap.”

On the earnings front, Five9 will hold for its fourth quarter and fiscal year 2024 financial results conference call on Thursday, Feb. 20.

Shares Views On These Industrials Stocks

“I got out too soon,” Cramer said when asked about Emerson Electric Co. EMR. “Missed out on 20 points.”

As per the recent news, Aspen Technology, Inc. AZPN inked a deal to be acquired by Emerson Electric in an all-cash tender offer for $265 per share.

“I was surprised at the numbers being that strong,” Cramer said when asked about Oshkosh Corporation OSK. “Another great American company that just shot the lights out that no one's paying attention to it.”

Supporting that choice, UBS analyst Steven Fisher, on Monday, maintained Oshkosh with a Buy and raised the price target from $125 to $137, while Morgan Stanley analyst Angel Castillo increased the price target from $98 to $110.

Other Stocks In Focus

Cramer said no to BigBear.ai Holdings, Inc. BBAI and recommended to go with Palantir Technologies Inc. PLTR.

Last week BigBear.Ai announced it was awarded a prime indefinite delivery/indefinite quantity contract under the U.S. Department of Navy's SeaPort Next Generation program.

The Mad Money host said he can't recommend GameStop Corp. GME, saying it's a meme stock. He recommended Take-Two Interactive Software, Inc. TTWO.

On Dec. 10, GameStop reported third-quarter net sales of $860.3 million, down from last year’s third-quarter total of $1.08 billion. The total missed a Street consensus estimate of $887.7 million, according to data from Benzinga Pro.

Price Action:

• Emerson shares fell 1.6% to settle at $127.85 on Monday.
• Five9 shares fell 1.2% to close at $40.49 during the session.
• BigBear.ai shares fell 0.2% to settle at $4.23.
• Oshkosh shares fell 3.1% to close at $112.85 on Monday.
• GameStop shares fell 3.8% to settle at $25.89.

Read Next:

• Jim Cramer Says AppFolio Is A ‘Good One,’ But Summit Therapeutics? ‘Can’t Go There’

Photo: Shutterstock